Keywords: novartis, selects, 2nd, candidate, deal, uk-based, biopharmaceutical
Novartis selects 2nd candidate from R&D deal
Article | 27 November 2006
UK-based biopharmaceutical company Vernalis says that Swiss drug major Novartis has selected the second compound as a preclinical development candidate, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
